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Abstract
Background: Insulin-degrading enzyme (IDE) is an allosteric Zn
+2 metalloprotease involved in the degradation of many
peptides including amyloid-b, and insulin that play key roles in Alzheimer’s disease (AD) and type 2 diabetes mellitus
(T2DM), respectively. Therefore, the use of therapeutic agents that regulate the activity of IDE would be a viable approach
towards generating pharmaceutical treatments for these diseases. Crystal structure of IDE revealed that N-terminal has an
exosite which is ,30 A ˚ away from the catalytic region and serves as a regulation site by orientation of the substrates of IDE
to the catalytic site. It is possible to find small molecules that bind to the exosite of IDE and enhance its proteolytic activity
towards different substrates.
Methodology/Principal Findings: In this study, we applied structure based drug design method combined with
experimental methods to discover four novel molecules that enhance the activity of human IDE. The novel compounds,
designated as D3, D4, D6, and D10 enhanced IDE mediated proteolysis of substrate V, insulin and amyloid-b, while
enhanced degradation profiles were obtained towards substrate V and insulin in the presence of D10 only.
Conclusion/Significance: This paper describes the first examples of a computer-aided discovery of IDE regulators, showing
that in vitro and in vivo activation of this important enzyme with small molecules is possible.
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Introduction
Insulin degrading enzyme (IDE), an 113 kDa cytosolic metallo-
peptidase, found in bacteria, fungi, plants, and animals, is involved
in the clearance of a variety of peptides including insulin, amyloid-
b, glucagon, amylin, b-endorphin, insulin-like growth factor II
(IGF-2), atrial natriuretic peptide (ANP), transforming growth
factor a (TGF-a) [1,2,3]. IDE consists of two 56 kDa catalytic N-
and C-terminal domains having four structurally homologous ab
roll domains [4]. These two N- and C-terminal domains,
connected by a loop of 28 amino acid residues, constitute a large
catalytic chamber where peptides smaller than 70 residues can fit.
IDE can be in an open or closed state based on substrate-bound
and substrate-free crystal structures of IDE [5,6]. In the open state,
substrates can diffuse in and out of the chamber, while free and
bound substrates are degraded in the closed state. A unique feature
of substrate recognition of IDE is that N-terminal of the IDE
substrates make contact with a highly conserved region, named
exosite, located ,30 A ˚ away from the catalytic center prior to
cleavage [5]. This site allows proper positioning of the C-terminal
end of peptides, and these peptides are subsequently directed
towards the catalytic site.
There are several proposed mechanisms for the regulation of IDE
activity [7,8,9]. One other possibility towards regulation of IDE
activity is by small molecules, and it is possible to find small
molecules that bind IDE and regulate its activity for stabilizing
conformations or disrupting hydrogen bonding between N- and C-
terminal halves. The first known small molecules that bind and
activate IDE are ATP and other nucleotide polyphosphates [10,11].
ATP is reported as an inhibitor of IDE [11]; however, interestingly it
is found that it activates the degradation of shorter substrates by70
fold, higher than the wild type protein alone [12,13].
The regulation of IDE function with small molecule organic
compounds is becoming a very attractive strategy for the treatment
of AD and T2DM. Cabrol et al. introduced two novel compounds
that stimulated the proteolysis of only short peptides of IDE
synergistically with ATP using high-throughput screening [12]. To
ourknowledge,thesetwomoleculesaretheonlysmallmoleculesthat
enhance the catalytic activity of IDE reported in the literature. In
another study, a set of IDE peptide-inhibitors were designed to
regulate the catabolism and activity of insulin. These resulting
compounds were about 106 times more potent than existing
inhibitors, and crystallographic analysis revealed that inhibitors
stabilized IDE’s ‘‘closed,’’ inactive state [13]. In a recent study by
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discovered to increase the activity of IDE with selective binding to
the exosite [6]. However, this peptide was found to have low affinity
and high Km due to its failure to bind to the exosite and catalytic site
simultaneously. The discovery of bradykinin as a low affinity IDE
activator provided the knowledge basis for the design of molecules
that may modulate the function of IDE. Consistent with this finding,
we hypothesized that similar to bradykinin, binding of small
molecules to the IDE exosite could play a regulatory role in
substrate binding and subsequent IDE proteolysis.
In this study, we utilized structure based virtual screening
approach to identify novel compounds that bind IDE exosite to
enhance degradation of specific substrates by IDE. We performed
virtual screening of over one million small molecular weight
compounds, using the docking software Autodock 3.0.5. We
identified 10 hit compounds that have high binding energies with
the exosite of IDE, and further tested the effect of these
compounds with fluorogenic assay using substrate V, insulin and
amyloid-b. Three out of these 10 compounds, D3, D4 and D6,
have been found to enhance the activity of the IDE towards
insulin, substrate V and amyloid-b degradation, respectively, while
the fourth compound, D10, enhanced the proteolysis of both
substrate V and insulin by IDE. In addition, we show that
degradation of insulin by IDE can be enhanced in a cellular
setting, increasing the proteolysis of internalized insulin. In order
to demonstrate further that these compounds indeed bind to the
exosite of IDE, we used site-directed mutagenesis to synthesize
IDE with mutations at the exosite, and tested those mutants to see
whether such mutants have altered the effectiveness of our
compounds. Our experimental analysis demonstrated that muta-
tions of IDE exosite residues Gln363 and His332 to alanine
resulted in lower initial and maximum rate of proteolysis of insulin
by IDE. The novel compounds proposed in this study could serve
as initiators for lead optimization studies, which could ultimately
lead towards the design of compounds for the treatment of
hyperinsulinemia and Alzheimer’s disease.
Results
Analysis of Molecular Dynamics Simulation
We applied an energy minimization and molecular dynamics
simulation for the refinement of atom coordinates of IDE (pdb id:
2G47) as described previously [14] . This procedure is required to
have a 3D structure similar to IDE at physiological conditions
before docking calculations in order to calculate binding energies
at realistic conditions. The simulation showed a slight increment
after minimization up to approximately 0.4 ns, and then no
significant deviations for the rest of the simulation were observed,
which demonstrated the convergence of RMSD and the stability
of the given structure within 1.2 ns time period. The final structure
at the end of the MD simulation was employed for molecular
docking calculations.
Virtual screening and detailed docking
The database of over 1,000,000 commercially available com-
pounds was used for virtual screening as described previously [14]
and the experimentally determined inhibition constant (IC50)v a l u e s
were shown to support computational predictions about the activity
of the compounds found [15,16]. The study of Malito et al.
confirmed that binding of a short peptide substrate, bradykinin, to
the exosite region of IDE enhanced the degradation of short peptide
substrate [6]. Therefore, the exosite region was selected as the target
region for computer-aided drug design. The free binding and
docking energies of the selected candidates were in the range of 29
to 15 kcal/mol. The top-ranking compounds from the virtual
screening were chosen for further detailed docking simulations.
Following the virtual screening, the selected compounds were
subjected to detailed -docking calculations at the exosite with
increased grid resolution (from 0.375 A ˚ to 0.180 A ˚). The
compounds with minimum binding energies were selected and
then analyzed according to important characteristics such as
docking positions, hydrogen bonding interactions with the exosite
residues (336–342 and 359–363) and close proximity, van der
Waals interactions, exposed surface area, and pocket occupancy.
Consideration of Lipinski rules [17], and visual analysis of
compounds in terms of compound conformations yielded a final
number of 10 compounds. A list of the top 10 compounds with
estimated binding and docking energies in both virtual screening
and detailed docking as well as their interactions with the residues
at the exosite are listed in Table 1 (see Figure S8 for molecular
structure of the compounds).
Computational analysis of the novel compounds
The structures and conformation of compounds D3, D4, D6
and D10 at the IDE exosite, and their interactions with IDE
residues and distances between interacting atoms are shown in
Figure 1. The threshold value for hydrogen bonding interaction is
considered as 3.5 A ˚; that is hydrogen bonding interaction is
established if a distance between a hydrogen donor atom and a
hydrogen acceptor atom is smaller than this threshold value as well
as the angle between these atoms. As shown in Figure 1A, D3
interacts with the exosite residue His336 and Gly361 and also
additional contacts were observed with Glu453 and Tyr609. D4
interacts with three exosite residues, Gly339, Gly361, Gln363
(Fig. 1B), and additional interactions were observed with His335
and Tyr609. As can be observed in Figure 1C, D6 creates
interactions with Gly361, Gln363 at the exosite and additional
interaction with His332 is also observed. Finally, D10 has
interactions with Gln363 residue at the exosite and His332 as
shown in Figure 1D.
It can be postulated that, binding of bradykinin at the exosite
stimulates the switch from close to open state; however, the
stability and duration of open state can be increased using more
efficient compounds. The conformational change for IDE is
required to enhance the catalytic activity due to its complex
Table 1. Binding free and docking energy scores of virtual
screening and detailed docking for the potential hit
compounds.
ID
Bind. Free
Energy
(kcal/mol)
Docking
Energy
(kcal/mol) Interacting residues
D1 211.01 212.33 His
332,H i s
336,G l y
339,G l y
361,A s n
418,T y r
609
D2 211.76 214.06 Gly
331,His
332,H i s
336,G l y
339,G l y
361,G l n
363, Tyr
609
D3 211.13 213.11 His
336,G l y
361,G l u
453, Tyr
609
D4 211.16 213.15 His
335,G l y
339,G l y
361,G l n
363, Tyr
609
D5 212.99 214.89 His
332,H i s
335,H i s
336,G l y
361
D6 211.77 214,23 His
332,G l y
361,G l n
363
D7 212.06 215.14 Gly
331,H i s
332,H i s
335,H i s
336,G l y
339,G l y
361 Gln
363
D8 211.57 213,95 His
332,G l y
339,G l n
363, Tyr
609
D9 212.18 215.26 Asn
329,Gly
331,H i s
332,H i s
336,G l y
361,G l n
363,A s n
418
D10 211.48 211.11 His
332,G l n
363
doi:10.1371/journal.pone.0031787.t001
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can enter into a partially opened chamber due to their small sizes;
consequently interacting with exosite residues with similar
mechanism as bradykinin. This may result in a conformational
change of IDE by reducing its catalytic chamber size, and this shift
may yield the open state which will subsequently allow substrates
to interact with the catalytic site [6].
Effect of novel compounds on the enzymatic activity
of IDE
The 10 compounds given in Table 1 were subjected to further
characterization and their effect was measured on the proteolytic
activity of IDE using different substrates. Initially, activity assays
were carried out at fixed 20 mM concentrations for all molecules to
identify the effect of those compounds on IDE activity. IDE
activity was quantified by monitoring the change in fluorescence
for the proteolysis of fluorogenic-substrate V, FITC- insulin-bound
antibody, and FAbB by recombinant human IDE purified from
E.coli BL21 [6,18,19]. Analysis for the effect of compounds on IDE
activity showed that, D3 increased the IDE-mediated insulin
degradation by 72% (Fig. S1B), while D4 enhanced IDE-mediated
substrate V and insulin degradation by 36% and 60%, respectively
(Fig. S1A, B). Also, D6 increased the amyloid-b degradation by
20% (Fig. S1C). Further, D10 enhanced IDE-mediated FITC-
insulin-mAb and substrate V degradation by 290% and 65%,
respectively (Fig. S1A, B). Next, an EC50 value of each molecule
that enhanced IDE activity was determined with a dose response
assay, where specific activity of IDE was measured with different
concentrations of the lead compounds and then the plot was fit to
Sigmoidal Hill-4 parameter equation. Calculated EC50 values for
D4 were found as 7 mM and 13 mM for substrate V, and insulin
degradation, respectively (Fig. S2A, B). EC50 value for D3 on
insulin degradation was approximately measured as 20 mM
(Fig. S2C), whereas EC50 value for D6 on amyloid-b degradation
was 2 mM (Fig. S2D). Furthermore, EC50 values for D10 were
found as 13 mM and 12 mM for substrate V, and insulin
degradation, respectively (Fig. S2E, F). Among all these four
compounds, D10 seems to be the potent activator of IDE, when
proteolysis of insulin is considered.
The effect of ATP on insulin degradation was further tested
with compounds D3, D4 and D10, and we observed that IDE
activity did not change significantly when proteolysis was carried
out in the presence of 0.1 mM ATP (Fig. S3). Cabrol et al. found a
synergetic effect of ATP with potential compounds; thereby in
order to test the effect of ATP on IDE activity in the presence of
activators, we, performed a fluorogenic assay with different
concentrations of the novel compounds [12]. The novel
compound, D10 enhanced the substrate V degradation by 60%,
however this compound is more potent on insulin degradation
with an increase in the IDE activity of 290% (Fig. S3C). Finally,
ATP had no effect on amyloid-b degradation in presence of D6
(data not shown).
Effect of Compounds on Initial Rate of Proteolysis by IDE
In order to explore the effect of lead compounds on the initial
activity of the IDE, we carried out time series experiments both in
the presence and absence of the lead compounds. Among the lead
compounds, only D10 increased the initial rate of substrate V
degradation by about 2 fold (Fig. S4). On the other hand, D3, D4,
and D10 significantly increased the initial rate of proteolysis
activity of IDE on FITC-insulin bound with antibody by about,
7.5-, 12-, and 49-fold, respectively (Fig. 2A). D3, D4 and D10 did
not have any effect on the proteolysis activity of IDE for amyloid-b
(Fig. S1C). Furthermore, our results indicated that D6 accelerated
the initial rate of amyloid-b proteolysis by IDE by a factor of 1.3
(Fig. S4B). It is observed that initial activation of enzyme increased
even at very low concentrations of lead compounds (Fig. 2A).
Interaction of these compounds with exosite residues similar to
bradykinin might be stabilizing the enzyme conformation in its
active state. As a result, interaction of the lead compounds with
IDE may change the conformation of IDE by reducing the size of
the catalytic chamber, and this shift may promote the open state of
Figure 1. The interactions between compound D3 and the exosite of IDE. The compound is shown as purple sticks, amino acid residue
belonging to the IDE exosite are shown as red sticks (Gly361) (A). The interactions between compound D4 and the exosite of IDE. The compound is
shown as green sticks, amino acid residues belonging to the IDE exosite are shown as red sticks (Gly339, Val360, Gly361) (B). The interactions between
compound D6 and the exosite of IDE. The compound is shown as purple sticks; amino acid residues belonging to the IDE exosite are shown as red
sticks (Gly363, His332, Gly361) (C).The interactions between compound D10 and the exosite of IDE. The compound is shown as purple sticks; amino
acid residues belonging to the IDE exosite are shown as red sticks (Gly363, His 332) (D).
doi:10.1371/journal.pone.0031787.g001
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Malito et al. [6] Structurally stabilized IDE in open state may
subsequently allow substrates to interact with the catalytic site in
an efficient manner and result in sharp increases in initial rates
(Vo) even in the presences of low concentration of the compound.
Verification of exosite as the binding site by lead
compounds via directed mutagenenesis
Since D10 has been found as the strongest activator of IDE
towards the proteolysis of insulin, we analyzed the binding site of
the compound D10 for the further analysis. According to the
computational results, D10 binds to Gln363 at the IDE exosite
and His332 (Fig. 1D). We carried out site-directed mutagenesis by
replacing these amino acids into Ala in order to verify that D10
indeed binds to this region via these amino acids. We first mutated
Gln363 to Ala and then expressed and purified mutant protein
through nickel resin. The effect of D10 on the proteolytic activity
of mutant IDE (Gln363Ala) was measured towards FITC-insulin-
mAb degradation. Enzymatic in vitro assay showed that enhanced
activation in the presence of D10 was reduced by 10-fold with
mutant IDE (Gln363Ala). The activation was about 49-fold in the
presence of D10 with wild type IDE (Fig. 2B). Although mutant
IDE activity was less responsive to D10 compound compared to
wild type IDE, it appeared as if D10 were interacting with IDE
Figure 2. Measurement of initial insulin binding rates of IDE. Effects of different drugs (D3, D4, and D10) on initial binding rate of insulin (A).
Initial insulin binding rates of mutant IDE in the presence of 20 mM D10 (B). Data are mean 6SEM for 3 independent experiments (p,0.0001).
doi:10.1371/journal.pone.0031787.g002
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Therefore, we generated a double mutant IDE (Gln363Ala,
His332Ala) in order to eliminate the binding of D10 to the exosite
region completely. Analysis of double mutant demonstrated that
D10 could not bind to IDE exosite (Fig. 2B). This was verified by
enzymatic assay which resulted in similar initial rate of proteolysis
for both double mutant and wild type IDE (Fig. 2B). If Gly363
were in fact one of the amino acids that interacts with D10, one
would expect to see amino acids (Gly 362 and Lys 364) that are
adjacent to the Gly363 would not contribute to the binding of the
D10. Therefore we mutated adjacent amino acids (Gly 362 and
Lys 364) to Ala and showed that D10 compound could in fact
interact with Gly363. The initial rate of proteolytic activity of
double mutant IDE (Gln363Ala, His332Ala) is comparable to wild
type IDE, where D10 increased the activity of IDE over 49-fold as
can be observed from Figure 2B. These results suggest that D10
binds to IDE through Gly363 at the exosite, and His 332, and in
turn can increase the catalytic activity in a specific manner.
Furthermore, we have carried out competition assay with
bradykinin in the presence of D10 in order to demonstrate further
that D10 binds to the exosite region of IDE. Assay is performed
with three different concentrations of bradykinin (2.1, 4.2 and
8.4 mM) and with varying concentrations of D10. We chose
2.1 mM and 8.4 mM concentrations as minimum and maximum
amounts of bradykinin in this experiment, as Km value for
bradykinin was measured as 4.2 mM in a previous study (Fig. S6)
[6]. This experiment demonstrated that degradation of insulin in
the presence of D10 was decreased by about 50% when there was
bradykinin in the proteolytic medium, even at high concentrations
of bradykinin (8.4 mM) (Fig. S6). This could be attributed to the
competition of D10 with bradykinin to access to the exosite
residues of His332 and Gln363 (Table 1).
Cell Viability Test
We characterized the activity of novel compounds in a cellular
assay to establish whether there were any cytotoxic effects. We
used an established MTT (3-(4,5-dimethylthiazolyl-2)-2, 5-diphe-
nyltetrazolium bromide or thiazolyl blue) method using HELA
cells to determine whether the small molecule affects cell viability
[20]. In this method, a purple formazan dye forms as a result of
the cleavage of the yellow tetrazolium MTT within metabolically
active cells. The resulting precipitate of the intracellular formazan
can be dissolved in a detergent solution and quantified
spectrophotometrically at 595 nm. We measured the cytotoxicity
by incubating HELA cells in the presence of novel compounds at
concentrations ranging from 1 to 100 mM for 24 h. Cell viability
was measured using the MTT method after 12 h culture. The
extent of cell death was expressed relative to a control containing
DMSO. We found that D4 did not affect viability significantly
from a concentration of 2 mM to a concentration as high as
100 mM at which cells remained 60% viable (Fig. S5B). We also
observed that approximately 85% of cells remained viable at a
concentration of 7.5 mM, which is close to the EC50 value of D4.
The other novel compounds, D3 and D10 did not demonstrate
any toxicity at high concentrations (Fig. S5A, D). We observed
that D6 showed toxicity at higher concentrations (Fig. S5C), while
D6 is not toxic at its EC50 value of 2 mM. These results indicate
that lead compounds are not toxic to mammalian cells. Therefore,
as a next step we tested the effects of lead compounds on insulin
catabolism using HeLa cells.
Cellular-based degradation of insulin
Biochemical analysis indicated that lead compounds
increased the activity of IDE enzyme towards different substrates,
predominantly towards insulin. In order to demonstrate further
that these molecules can display activity in vivo conditions, we
examined the effects of lead compounds on insulin catabolism in
cultured cells. It was shown that HeLa cells express insulin
receptor, and thus take FITC-labeled insulin inside and degrade it
intracellularly [13,21,22]. First, FITC-insulin was added to the
culture that contains HeLa cells and incubated for 2 hours in
order to allow for sufficient uptake of FITC-insulin by HeLa cells.
In order to ensure that FITC-labeled insulin is translocating into
the cells through insulin uptake receptor, and that cytoplasmic
IDE can degrade FITC- insulin, we conducted live cell imaging of
HeLa cells, and recorded fluorescence. At various time points
compounds, D3, D6, and D10, were added; and cells were washed
with Hank’s balanced salt solution (HBSS), the these cells were
collected and lysed with appropriate buffer. After centrifugation,
cell free extracts were used to measure the change in fluorescence
by luminometer. The cells that were treated with D10 and D3
displayed increases in the intensity of fluorescence. Consistently,
we observed higher fluorescence signal from D10 and D3 treated
cells suggesting higher FITC-insulin degradation by cytosolic IDE
(Fig. 3A). Compound D10 increased in vivo proteolysis of FITC-
insulin by about 32 fold with HeLa cells compared to control
group (Fig. 3A). However, for the case with compound D6, which
was used as a control, fluorescence intensity did not change
significantly compared to the samples treated with D10 and D3.
These findings are consistent with the data obtained by in vitro
assay, showing enhanced degradation of insulin by D10 and D3
(Fig. 3A). Notably, D6 had no effect on insulin catabolism as
expected (Fig. 3A). Figure 3B shows fluorescence microscope
images of HeLa cells ten minutes after the addition of compounds
D3, D6, D10, as well as images of HeLa cells treated with only
DMSO and no-FITC insulin as controls. This figure further
verifies the significant increase in fluorescence observed in the
presence of compound D10, which is consistent with our in vitro
assay (Fig. 3B).
Discussion
Virtual screening has become one of the major components in
the drug discovery approach within the last few years [23]. When
3D structure of the protein is known, structure based screening is
preferred, whereas ligand based screening is utilized when
experimental inhibition/activation data is available in the
literature [24]. The presence of the crystal structure of IDE makes
structure based drug design a viable approach to find novel
molecules that could regulate overall activity of the IDE. Here, we
employed structure based virtual screening, enzymologic charac-
terization, cellular based assay to discover potent compounds that
regulate IDE activity. The hit rate in experimental high-
throughput screening (HTS) efforts of drug-like compounds varies
from 0.01 to 1% [25]. Cerchietti et al. achieved a 10% hit rate
using computer-aided drug design to identify BCL6 inhibitors
[26]. In another study, novel inhibitors of protein tyrosine
phosphatase-1B were identified with a hit rate of 34.8% (127
potent compounds out of 365 selected molecules) [27]. Here, we
achieved 40% (4 out of 10 tested) of hit rate using structure based
drug discovery approach, which is a faster, more economic and
efficient strategy compared to other HTS or experimental
screening techniques. We utilized structure based virtual screening
approach to identify four compounds that bind to IDE exosite,
and have potential to enhance cleavage of specific substrates by
IDE. Three compounds, D3, D4 and D6, have been found to
enhance the activity of the IDE towards insulin, substrate V and
amyloid-b degradation, respectively, while compound D10,
Insulin Degrading Enzyme Activity Regulation
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recent study by Cabrol et al. showed enhanced degradation of
amyloid-b by two compounds, Ia1 and Ia2, in the presence of short
peptide substrates and ATP, while in other study by Leissring et al.
[12] a rational design approach based on analysis of combinatorial
peptide mixtures was used to develop IDE inhibitors [12,13]. To our
knowledge, the compounds discovered in this study are the first
potential lead compounds that enhance IDE activity independently
of ATP or small IDE substrates. The optimization of the structure of
small molecular weight organic compounds identified in this paper
and further in vivo characterization may make it possible to design
molecules with therapeutic utility for hyperinsulinemia, type 2
diabetes and Alzheimer’s disease.
The most significant novelty that these compounds have is that
they are the only known selective and independent activators of
IDE. Specifically, to our knowledge compound D10 is the only
potent small molecule discovered to increase proteolysis of insulin
by IDE. The distinctive IDE structure made it difficult to discover
compounds with therapeutic value, as IDE has two distinct
domains with C and N terminal halves, and can only degrade its
substrates when the protease is in closed configuration. Previous
study by Malito et al. highlighted the complexity involved in the
substrate binding and recognition mechanism of IDE, and
demonstrated that IDE uses its exosite to anchor the N-terminus
of its substrates which are then cleaved through a stochastic
process at the catalytic site [6]. Previous crystal structures of
bradykinin with IDE also showed that bradykinin can only bind to
the exosite but could not reach to the catalytic site. This
observation also suggested that bradykinin could play a regulatory
role to enhance substrate binding and degradation by reducing the
entropy of short peptides in the chamber. The lead compounds
that are presented in this paper may enhance binding of different
substrates to the exosite and then direct substrates to the catalytic
site for further proteolysis. Our site directed mutagenesis and
competition assay at the IDE exosite results with these novel
compounds also suggest that binding of compounds to the exosite
indeed occurs, and that binding to the exosite is critical for
enhancing substrate specific degradation by IDE. It is established
that catalytic rate of IDE is affected by flexibility of substrates as
well as ability of substrates to gain access to the catalytic chamber.
Furthermore, we observed that bradykinin competed with
compound D10 for the binding to the IDE exosite. These results
suggest that the compounds enter into the partially opened
catalytic chamber during IDE conformational switch, and to direct
substrates towards the catalytic site resulting in enhanced catalysis
for specific substrates.
Various studies have shown that ATP enhances the IDE activity
of some substrates and it sometimes plays a synergistic role with
Figure 3. Effects of IDE activators on insulin catabolism in Hela cells. Compound D10 and D3 show ,%240 and %65 increases respectively
in the magnitude of IDE activity for insulin degradation in HeLa cells (A). D6 does not change insulin degradation as expected (A). Representative
images of live HeLa cells pre-loaded with FITC-insulin and imaged at various drugs (20 mM) and absence of drugs (B). Data are mean 6SEM for 3
independent experiments (p,0.0002).
doi:10.1371/journal.pone.0031787.g003
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IDE for insulin degradation did not change in the presence of
ATP. The concentration dependent D3, D4 and D10 experiments
were repeated in the absence and presence of ATP, and the
activity of IDE showed the same trends in these conditions. Song et
al. showed that nucleotides have no effects on the hydrolysis of the
physiological substrates insulin and amyloid-b peptide [10]. We
also observed that ATP has no effect on the insulin catabolism in
the presence of D3, D4, and D10 in our experiments (see Fig. S3).
The most significant impact of the compounds reported in this
paper from a biomedical point of view is that these compounds
have the potential to have medicinal value on insulin signaling.
IDE activators with desirable pharmacokinetic properties may be
significant for diabetes, as it is questionable to combat with
diabetes or hyperinsulinemia through genetic mutations of IDE
gene [28]. For example, IDE knockout mice have been shown to
develop diabetic phenotype, whereas overexpression of IDE in
Alzheimer’s disease mouse models have been shown to completely
eliminate amyloid plaque formation and downstream cytopathol-
ogy [29,30]. In contrast to the permanent lifelong activation of
IDE, drugs that only transiently enhance IDE activity for specific
substrates may be expected to improve glycemic control. As a
result, the goal of enhancing amyloid -b or insulin degradation by
pharmacological compounds has been regarded as best, but a
challenging objective due to the unusual properties of this enzyme.
Finally, the activators that are introduced in this study may
function as important tools to manipulate IDE experimentally.
The use of activators might also be important for experimental
and clinical settings. Further, these compounds would be useful to
address various questions related to the chemical biology of IDE.
Our cellular based assay demonstrated that compounds that
enhance degradation of insulin, D3, D6, and D10, not only
enhance degradation of insulin in vitro and in vivo but they are also
permeable through cell membrane which may allow for evaluation
of their roles in animal models for diseases such as hyperinsulin-
emia, diabetes, and Alzheimer’s.
Materials and Methods
Materials
cDNA of human insulin degrading enzyme (IDE) was obtained
from Prof. Richard A. Roth from Stanford University. Substrate V
was purchased from R&D systems, Inc. (Minneapolis, MN), FITC
and 1, 10- phenanthroline from Sigma, fluorescein-Ab-(1–40)-Lys-
biotin (FAbB) and bradykinin from Anaspec Corp (San Jose, CA),
Neutravidin- coated agarose beads from Thermo Scientific and
mouse anti human insulin from AbD Serotec.
Molecular dynamics simulation
The coordinate of the initial structure was obtained from the
Protein Data Bank (PDB id: 2G47) [4]. The reported structure was
a catalytically inactive IDE mutant IDE-E111Q in complex with
amyloid-b peptide (Ab 1–40) at 2.1 A ˚ . MD simulations were
carried out by using the NAMD software, version 2.6 with the
PARAM22 version of the CHARMM force field [31,32]. The
protein was solvated in a rectangular box including TIP3P water
molecules and counter ions. First, the system was minimized
through 10000 steps by keeping the backbone fixed, and then
backbone atoms were relaxed through 10000 steps. Next, the
system was heated to 310 K with 10 K increments (10 ps
simulation at each increment).
After the equilibration of the system, a molecular dynamics
simulation was carried out with constant temperature (310 K) and
pressure control using the Langevin piston method. The time-step
of the simulation was set to be 2 fs and, the bonded interactions,
the van der Waals interactions (12 A cut-off), and the long-range
electrostatic interactions with particle-mesh Ewald (PME) were
included in the calculations to define the forces acting on the
system. The damping coefficient was set to be 5 ps-1 using
Langevin dynamics to handle pressure control. The simulation
was carried out for 1.2 ns, and the final stable structure was used
later in the docking calculations.
Molecular Docking
For small docking calculations docking software AutoDock 3.05
which was available for public access was employed [33]. This
version of Autodock predicts the optimal conformations of the
receptor-ligand complex and report binding affinity scores by
assuming a structure model with a rigid receptor (protein) and a
flexible ligand. The scoring function of Autodock consists of
electrostatic, Lennard-Jones, hydrogen bond, solvation, and
torsional entropy terms. Lamarckian genetic algorithm (LGA)
was employed for the ligand conformational search. The residues
336–342 and 359–363 of IDE were taken as the targets for
docking, since this region was defined to be located in the exosite
of IDE [6].
Construction of expression plasmid for IDE protein
cDNA of hIDE was PCR amplified with primer sets that
contains unique restriction enzyme sites (XhoI and NotI) and
hexa-histidine tag (66His). The primers that have been used for
amplification of hIDE cDNA are forward primer: 59-
cttgcggccgcaatgcggtaccggtaccggctagcgtg-93 and reverse primer:
59- gtgctcgaggagttttgcagccatgaa-93. PCR reaction is performed in
total volume of 50 ml containing 100 ng of plasmid, 40 pmol of
each primer, 0.2 mM dNTPs, and 2 unit of Taq DNA
polymerase. 33 cycles of amplification reaction is performed with
the conditions of 95uC for 30 s, 55uC for 30 s and 72uC for 3 min.
The reaction mixture is kept at 95uC for 4 min before the first
cycle, and after the 33 rd cycle additional extension period is
applied at 72uC for 10 min. Then, PCR products were purified
through the gel extraction method and digested with Xho I and
Not I enzymes along with pET21-b bacterial expression vector.
Then, cDNA of hIDE were subcloned into pET21-b according to
the Maniatis et al. and named as pET21b-hIDE [34].
Site Directed Mutagenesis
Site-directed mutations of the specified hot spot residues were
introduced to hIDE by PCR as previously described using
appropriate plasmid [35]. The presence of the specific mutations
was verified by DNA sequencing at Burc Laboratory (Istanbul,
Turkey).
Expression and purification of IDE protein
pET21b-hIDE was transferred to E.coli BL21 cells for
expression of recombinant hIDE. Once cells reached to OD
A600 0.6–0.8, IPTG was added to a final concentration of
400 mM and hIDE was expressed at 37uC for 3 h. Next the cells
were harvested and sonicated in a lysis buffer which was composed
of 50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole,
100 mM PMSF, 50 mM protease inhibitor cocktail and 0.1 mg/ml
lysozyme at a pH of 8.0. The soluble protein fraction was
separated by centrifugation at 90006 g for 30 min, and filtered
through a Ni-NTA column. After rinsing with 20 mM
imidazole, the histidine-tagged enzyme was eluted by NaCl
and 250 mM imidazole buffer. The purified IDE was
concentrated using a dialysis tubing cellulose membrane
Insulin Degrading Enzyme Activity Regulation
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as mentioned previously [36]. The concentration of the IDE
protein was measured as 0.02 mg/ml. The integrity of hIDE
was characterized by electrophoretic separation and followed by
Western-Blot. Proteins using anti-His IgG and membrane were
visualized by the ECL plus system.
Degradation of Substrate V by IDE
To assess the utility of these novel compounds as chemical
regulators for IDE activity, we used fluorescence assay with fluoro-
genic substrate V (7-methoxycoumarin-4-yl-acetyl-NPPGFSAFK-
2, 4-dinitrophenyl). Reaction was carried out in the presence of
105 mlo f1 0mlo f4 0mM substrate V; 10 ml of 0.02 mg/ml of IDE
in 83 mlo f3 0 m MK H 2PO4 at pH of 7.3, and various
concentrations (0–35 mM) compounds and also with various time
intervals (0–4 hours). The reaction mixture was incubated at 37uC
for 2.5 h. The hydrolysis of substrate V was monitored using a
Tecan Safire2 microplate reader with excitation and emission
wavelengths set at 300 and 395 nm, respectively.
Binding of monoclonal antibody (mAb) to FITC-insulin
In order to measure degradation of insulin by IDE, FITC-
insulin is bound to the monoclonal mouse anti-human-insulin, so
that the rotation of free FITC and possible changes in fluorescence
polarization could be prevented. We performed enzymatic assays,
using only FITC-insulin bound antibody as a background
fluorescence and checked the effects of compounds on the
cleavage of FITC-insulin-mAb. FITC-insulin is bound to mouse
anti human insulin antibody in PBS at 37uC for 1 hour, which is
higher than the optimum time required to obtain maximum
binding of insulin-FITC conjugate and mAb [37]. It is observed
that 400 nM mAb completely binds to 50 nM FITC-insulin (Fig.
S7). Since molecular weights of FITC-insulin and mAb are about
5.8 kDa and 60 kDa respectively, we observed very slight shift in
the gel as expected. In figure S7, it is observed in lane 4 that
50 nM (100 ng) insulin is completely bound to 400 nM mAb in
lane 4 (Fig. S7). Lane 1 represents 400 nM antibody, lane 2 shows
100 nM insulin, and lane 3 expresses the binding between 400 nM
antibody and 100 nM insulin. The binding between insulin and
mAb is shown by performing (%5 and %15) native polyacrylamide
gel electrophoresis.
Degradation of FITC-insulin-mAb by IDE
The utility of these novel compounds were tested on
degradation of insulin by IDE. First insulin was labeled with
FITC as described previously [37]. Briefly, 500 mg insulin
dissolved in 1.5 ml of 0.1 M Na-carbonate, at pH 7, and
0.2 mM EDTA. Then, 4.5 mg FITC was dissolved in 200 ml
acetone and was added dropwise to previous solution at room
temperature for 20 h ([FITC]:[insulin], 3:1). Finally, unreacted
FITC was removed by dialysis and the FITC-insulin was stored at
220uC. The proteolysis of insulin by IDE was monitored by
measuring the changes in fluorescence, where the reaction was
carried out with 100 nM of FITC- insulin-mAb and IDE (80 ng)
in 100 mlK H 2PO4 buffer at a pH of 7.3. Reaction was carried out
at 37uC for different time intervals (0–4 hours). The increase in
fluorescence was monitored by using Fluoroskan Ascent FL
microplate reader (Thermo).
FAbB degradation assay
This assay was performed as follows: 10 mlo f5 0n Mo fF A bB
was dissolved in a buffer which consisted of 50 mM HEPES,
100 mM NaCl, % 0,05 (v/v) bovine serum albumin, at a pH of
7.4. The reaction was initiated in a total volume of 100 ml with
20 mM drugs by adding 20 ml of 0.02 mg/ml of IDE for 2.5 h at
37uC. The reaction was stopped by adding 2 ml of 100 mM of
protease inhibitor (1, 10-phenanthroline). Uncleaved FAbB was
precipitated with Neutravidin- coated agarose beads by gentle
rocking for 30 min. and centrifugation for 10 min at 14000 g. The
supernatant was transferred to the black 96 well plates and
increase in fluorescence (488 excitation, 525 emission) was
measured with a multi-label plate reader.
Enzymatic competition assay
The effect of the bradykinin on the clearance of insulin was
measured in the presence of compound D10. Competition
reactions were carried out at 37uC by mixing 90 mlo f1 0n M
FITC insulin in 50 mM potassium phosphate buffer (pH 7.3) and
different concentrations of bradykinin (2.1 mM, 4.2 mM and
8.4 mM). Various concentrations of D10 was added (0–50 mM)
and reaction was initiated with the addition of 80 ng IDE. The
fluorescence increase was monitored by using Fluoroskan Ascent
FL microplate reader (Thermo).
Kinetic analysis
The effect of the lead compounds on the initial rate of
proteolysis of IDE was determined by measurement in fluores-
cence with time both in the presence and absence of the lead
compounds. The kinetic data for IDE-mediated insulin, substrate
V and amyloid-b degradation were plotted and fitted using
SigmaPlot software (Sigmoidal, Hill, 4 parameter). For the initial
rate calculations, kinetic data were fitted using SigmaPlot software
(Hyperbola; Single Rectangular I, 3 Parameter).
Cell -based degradation of insulin
Cells were cultured at 37uC under a humidified atmosphere of
5% CO2 in medium supplemented with 10% fetal bovine serum.
Then, FITC-insulin was added to cell medium and incubated for
2 h at 37uC. Next, compounds were loaded at different time
intervals separately. Cells were washed with Hank’s balanced salt
solution (HBSS), then disrupted with 16 passive lysis buffer.
Fluorescence was measured with a luminescence multi-label plate
leader, and changes in fluorescence was imaged by fluorescence
microscope at Burc Laboratory (Istanbul, Turkey).
MTT assay for evaluating cell viability
The cytotoxicity assay was performed using human cervical
cancer HeLa cells. Cells were cultured at 37uC under a humidified
atmosphere of 5% CO2 in medium supplemented with 10% fetal
bovine serum and dispersed in replicate 96- well plates with
2.5610
4 cells/well. Compounds were then added. After 24 hours
exposure to the chemical compounds, the cell viability was
determined by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenpyltetrazo-
lium bromide (MTT) assay [38]. The optical density (OD) of the
wells was determined using ELISA plate reader at a test
wavelength of 600 nm and a reference wavelength of 630 nm.
Each measurement was carried out in triplicate.
Supporting Information
Figure S1 The effect of selected compounds on the proteolytic
activity of IDE. Compound D4 and D10 show ,%36 and %60
increase respectively in the magnitude of IDE activity for substrate
V degradation (*p,0.0006) (A). Compound D3 , D4 and D10
show ,72%, 60% and %275 increase respectively in the
magnitude of insulin binding (*p,0.02, **p,0.003,
***p,0.0003) (B). Compound D6 increases the IDE-mediated
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6SEM for 3 independent experiments.
(JPG)
Figure S2 Measurement of the increase of IDE activity for
substrate V (A), and insulin (B) degradation in the presence of D4
at concentrations ranging from 0.02 to 40 mM. Increase in IDE
activity for insulin degradation in the presence of D3 (C). Increase
in IDE activity for amyloid-b degradation in the presence of D6
(D). Increase in IDE activity for substrate V (E), and insulin (F)
degradation in the presence of D10.Data are mean 6SEM for 3
independent experiments (p,0.0001).
(JPG)
Figure S3 The effect of compound D3 (A), D4 (B), D10 (C)o n
IDE mediated hydrolysis of insulin when tested in the presence
and absence of ATP (0.1 mM). Data are mean 6SEM for 3
independent experiments. Data are mean 6SEM for 3 indepen-
dent experiments (p,0.0001).
(JPG)
Figure S4 Measurement of initial rates of IDE in the catabolism
of substrate V (A) and Amyloid-b (B) in the presence of D4, D6, or
D10.Data are mean 6SEM for 6 independent experiments
(p,0.0001).
(JPG)
Figure S5 Measurement of the viability of HELA cells in the
presence of ranging concentrations of D3 (A), D4 (B), D6 (C) and
D10 (D)from 1 to 100 mM. Data are mean 6SEM for 6
independent experiments (p,0.00001).
(JPG)
Figure S6 Competition of bradykinin with compound D10.
Degradation of insulin in the presence of D10 is decreased
by about 50% when there was bradykinin in the proteolytic
solution.
(JPG)
Figure S7 Binding of monoclonal antibody (mAb) to insulin.
Lane 1: 400 nM mAb, lane 2: 400 ng insulin, lane 3: 400 nM
mAb and 400 ng insulin, lane 4: 400 nM mAb and 200 ng insulin,
lane 5: 1 mg/ml BSA.
(TIF)
Figure S8 Molecular structure of the compounds.
(PDF)
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